Ipamorelin

A synthetic pentapeptide with non-coded residues and a C-terminal amide, characterized in receptor-binding and structure-activity studies.

Molecular Profile

Type
Synthetic peptide (pentapeptide)
Molecular formula
C38H49N9O5
Molecular weight
711.9 g/mol
CAS number
170851-70-4
Amino acids
5
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Modification
N-terminal Aib; D-2-naphthylalanine; D-Phe; C-terminal amide.

Mechanism & Target Class

A synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) studied for its binding to a class A G-protein-coupled receptor in receptor-pharmacology assays. Non-coded residues (Aib, D-2-naphthylalanine, D-Phe) and C-terminal amidation are structural features examined for their contribution to binding selectivity and proteolytic stability across the analog series.

Storage & Handling

Lyophilized
-20°C; typically stable 24-36 months desiccated and protected from light.
Handling
Avoid freeze-thaw; aliquot; protect from light and moisture.

Primary Database

PubChem CID 9831659 ↗

References (19)

  1. Reviews

    1

    Buscail E, Deraison C. (2022). Br J Pharmacol

    DOI: 10.1111/bph.15800PubMed 35043975

  2. 2

    Ishida J, et al. (2020). JCSM Rapid Communications

    DOI: 10.1002/rco2.9

  3. 3

    Sinha DK, et al. (2020). Transl Androl Urol

    DOI: 10.21037/tau.2019.11.30PubMed 32257854

  4. Clinical

    4

    Beck DE, et al. (2014). Int J Colorectal Dis

    DOI: 10.1007/s00384-014-2030-8PubMed 25331030NCT00672074

  5. 5

    Gobburu JVS, et al. (1999). Pharm Res

    DOI: 10.1023/A:1018955126402PubMed 10496658

  6. Primary research

    6

    Mohammadi E, et al. (2020). J Exp Pharmacol

    DOI: 10.2147/JEP.S249747PubMed 32801950

  7. 7

    Semenistaya E, et al. (2015). Drug Test Anal

    DOI: 10.1002/dta.1787PubMed 25869809

  8. 8

    Greenwood-Van Meerveld B, et al. (2012). J Exp Pharmacol

    DOI: 10.2147/JEP.S35396PubMed 27186127

  9. 9

    Aagaard NK, et al. (2009). Growth Horm IGF Res

    DOI: 10.1016/j.ghir.2009.01.001PubMed 19297225

  10. 10

    Venkova K, et al. (2009). J Pharmacol Exp Ther

    DOI: 10.1124/jpet.108.149211PubMed 19289567

  11. 11

    Adeghate E, Ponery AS. (2004). Neuro Endocrinol Lett

    PubMed 15665799

  12. 12

    Jiménez-Reina L, et al. (2002). Histol Histopathol

    DOI: 10.14670/HH-17.707PubMed 12168778

  13. 13

    Andersen NB, et al. (2001). Growth Horm IGF Res

    DOI: 10.1054/ghir.2001.0239PubMed 11735244

  14. 14

    Lall S, et al. (2001). Biochem Biophys Res Commun

    DOI: 10.1006/bbrc.2000.4065PubMed 11162489

  15. 15

    Svensson J, et al. (2000). J Endocrinol

    DOI: 10.1677/joe.0.1650569PubMed 10828840

  16. 16

    Malmlöf K, et al. (2000). Growth Horm IGF Res

    DOI: 10.1054/ghir.1999.0128PubMed 10629165

  17. 17

    Johansen PB, et al. (1999). Growth Horm IGF Res

    DOI: 10.1054/ghir.1999.9998PubMed 10373343

  18. 18

    Ankersen M, et al. (1998). J Med Chem

    DOI: 10.1021/jm9801962PubMed 9733495

  19. 19

    Raun K, et al. (1998). Eur J Endocrinol

    DOI: 10.1530/eje.0.1390552PubMed 9849822